- Details
- Fred Saad joins Alicia Morgans in a discussion on the final overall survival data from the PROpel trial, a randomized controlled trial aimed to address the first-line mCRPC question in patients who have not been treated with a novel hormonal agent in the mCRPC setting. Patients were randomized to receive abiraterone and prednisone or abiraterone and olaparib. The trial's primary endpoint was radio...
|
- Details
- Elena Castro and Alicia Morgans discuss the use of PARP inhibitors and their combinations in advanced prostate cancer. They discuss data from the TRITON3, TALAPRO-2, and PROpel studies that help to fill in gaps in the current understanding. Elena discusses the timing of PARP inhibitors versus docetaxel in HRR mutations, based on TRITON3 data. The TALAPRO-2 study showed a difference in radiographic...
|
- Details
- Alicia Morgans converses with Noel Clarke about the significance of biomarkers in castration-resistant prostate cancer. Dr. Clarke highlights the clinical importance of recognizing diversity among prostate cancer patients, particularly considering age and associated comorbidities. Noting that many patients, especially from socially deprived backgrounds, face challenges due to comorbidities, he und...
|
- Details
- In this UroToday Journal Club, Zachary Klaassen reviews the PROpel study and the New England Journal of Medicine Evidence publication entitled Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer . PROpel is a randomized phase III trial of abiraterone plus olaparib versus abiraterone plus placebo as first-line therapy for patients with metastatic castration-resistant prosta...
|
- Details
- Fred Saad joins Alicia Morgans in a discussion focusing on the biomarker analysis and updated results from the Phase III PROpel trial of abiraterone and olaparib vs abiraterone and placebo as first-line therapy for patients with metastatic castration-resistant prostate cancer (mCRPC). This updated analysis provides more detail on patients with HRR mutations in the PROpel trial. In this biomarker a...
|
- Details
- Noel Clarke joins Alicia Morgans in discussing an updated analysis and updated results from the Phase III PROpel trial of abiraterone and olaparib vs abiraterone and placebo as first-line therapy for patients with metastatic castration-resistant prostate cancer (mCRPC). PROpel was born out of positive findings from the PROfound trial and a Phase II study, known as Study 08, which looked at whether...
|
- Details
- Alicia Morgans speaks with Neal Shore, focusing on the PROpel study which evaluates the efficacy of Olaparib and Abiraterone versus Abiraterone alone in treating first-line metastatic castration-resistant prostate cancer. Dr. Shore expresses excitement over the positive findings, particularly the benefits seen across all patient populations, not just those with HRR mutations. The conversation delv...
|
- Details
- Drs Maha Hussain and Fred Saad join Dr Alicia Morgans in a conversation on PARP combination therapy in prostate cancer and the status of its use in clinical practice. In this context, the group discusses the PROpel and the MAGNITUDE studies data and how the data can be used in clinical practice. Biographies: Maha Hussain, MD, FACP, FASCO, is the Genevieve Teuton Professor of Medicine in the Divisi...
|
- Details
- Fred Saad joins Alicia Morgans to discuss the results of the PROpel phase 3 trial of olaparib and abiraterone versus placebo and abiraterone as first-line therapy for patients with metastatic castration-resistant prostate cancer (mCRPC). Biographies: Fred Saad, MD, FRCS, Professor and Chief of Urology, Director of GU Oncology, Raymond Garneau Chair in Prostate Cancer, University of Montreal Hospit...
|
